Kenna Nagy

Kenna Nagy

Auto-generated profile, based on publicly available information

Kenna Nagy

Department of Immunology and Microbiology, the Scripps Research Institute, La Jolla, CA 92037, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 April 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
LHLinling He
Linling He
NTNetanel Tzarum
Netanel Tzarum
XLXiaohe Lin
Xiaohe Lin
BSBenjamin Shapero
Benjamin Shapero
CSCindy Sou
Cindy Sou
Jiang ZhuJiang Zhu
Jiang Zhu
An HCV vaccine strategy displays optimized E2 cores on nanoparticles for eliciting a cross-neutralizing B cell response.

4 December 2019 in Gastroenterology
Verified
Journal Article
Closed access
FCFang Chen
Fang Chen
KNKenna Nagy
Kenna Nagy
DCDeborah Chavez
Deborah Chavez
SWShelby Willis
Shelby Willis
RMRyan McBride
Ryan McBride
MLMansun Law
Mansun Law

24 July 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
NTNetanel Tzarum
Netanel Tzarum
EGErick Giang
Erick Giang
RKRameshwar U. Kadam
Rameshwar U. Kadam
FCFang Chen
Fang Chen
KNKenna Nagy
Kenna Nagy
MLMansun Law
Mansun Law
To achieve global elimination of hepatitis C virus (HCV), an effective cross-genotype vaccine is needed. The HCV envelope glycoprotein E2 is the main target for neutralizing antibodies (nAbs), which aid in HCV clearance and protection. E2 is structurally flexible and functions in engaging host receptors. Many nAbs bind to the “neutralizing face” on E2, including several broadly nAbs encoded by the VH1-69 germline gene family that bind to a similar conformation (A) of this face. Here, a previously unknown conformation (B) of the neutralizing face is revealed in crystal structures of two of four additional E2–VH1-69 nAb complexes. In this conformation, the E2 front-layer region is displaced upon antibody binding, exposing residues in the back layer for direct antibody interaction. This E2 B structure may represent another conformational state in the viral entry process that is susceptible to antibody neutralization and thus provide a new target for rational vaccine development.

28 June 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FAFernando Aleman
Fernando Aleman
NTNetanel Tzarum
Netanel Tzarum
LKLeopold Kong
Leopold Kong
KNKenna Nagy
Kenna Nagy
JZJiang Zhu
Jiang Zhu
MLMansun Law
Mansun Law
Significance: Hepatitis C virus (HCV) infects 1–2% of the world’s population, but a vaccine to limit spreading of this silent killer is unavailable. A leading strategy in vaccine design to counter the genetic variability of HCV is to elicit broadly neutralizing antibodies (bnAbs) targeting conserved viral epitopes. The HCV antigenic site 412–423 (AS412) is highly conserved and a prime vaccine target. In this study, the genetic and structural properties of murine bnAbs targeting AS412 were determined. Using specific molecular interactions encoded in the antibody germline genes and those acquired by somatic hypermutation, two distinct antibody lineages recognize AS412 in near identical conformations. The results provide key insights in the development of HCV bnAbs for rational vaccine design.

1 March 2024 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
ACAnne Costanzo
Anne Costanzo
DCDon Clarke
Don Clarke
MHMarie Holt
Marie Holt
SSSiddhartha Sharma
Siddhartha Sharma
KNKenna Nagy
Kenna Nagy
LTLuc Teyton
Luc Teyton
Type 1 diabetes (T1D) is a prototypic T cell–mediated autoimmune disease. Because the islets of Langerhans are insulated from blood vessels by a double basement membrane and lack detectable lymphatic drainage, interactions between endocrine and circulating T cells are not permitted. Thus, we hypothesized that initiation and progression of anti-islet immunity required islet neolymphangiogenesis to allow T cell access to the islet. Combining microscopy and single cell approaches, the timing of this phenomenon in mice was situated between 5 and 8 wk of age when activated anti-insulin CD4 T cells became detectable in peripheral blood while peri-islet pathology developed. This “peri-insulitis,” dominated by CD4 T cells, respected the islet basement membrane and was limited on the outside by lymphatic endothelial cells that gave it the attributes of a tertiary lymphoid structure. As in most tissues, lymphangiogenesis seemed to be secondary to local segmental endothelial inflammation at the collecting postcapillary venule. In addition to classic markers of inflammation such as CD29, V-CAM, and NOS, MHC class II molecules were expressed by nonhematopoietic cells in the same location both in mouse and human islets. This CD45− MHC class II+ cell population was capable of spontaneously presenting islet Ags to CD4 T cells. Altogether, these observations favor an alternative model for the initiation of T1D, outside of the islet, in which a vascular-associated cell appears to be an important MHC class II–expressing and –presenting cell.

29 August 2026 in The Journal of Immunology
Verified
Journal Article
Open access
KNKenna Nagy
Kenna Nagy
JNJeffery Noble
Jeffery Noble
SDShenglou Deng
Shenglou Deng
RHRobert Hincapie
Robert Hincapie
ACAnne Costanzo
Anne Costanzo
LTLuc Teyton
Luc Teyton
Current glycoconjugate vaccines often fail to induce durable B cell memory or to provide sufficiently high-affinity antibodies limiting their utility for prophylactic protection against most bacterial and fungal pathogens. We address this limitation by engineering a chemically functionalized protein nanoparticle vaccine capable of eliciting protective nanomolar affinity antiglycan antibodies and long-term humoral memory. This platform incorporates a combination of two B cell–focused adjuvants, a TLR7 agonist and a natural killer T cell agonist, in order to enhance the antiglycan antibody maturation and memory formation. To define the contributions of each pathway, the antiglycan responses were evaluated at early and late time points following immunization. Although mice deficient in both TLR7 and natural killer T cell signaling revealed diminished primary immunization responses, an unexpectedly robust antiglycan antibody titer still developed and persisted for at least 1 yr after a two-dose immunization. These results indicate that durable antiglycan humoral immunity can develop independent of the chosen adjuvant pathways and may be driven by intrinsic adjuvanticity of the recombinant bacteriophage nanoparticle. Mechanistically, this effect was associated with an inflammatory response in which IFNγ and IL-1α appeared to play important roles. Together, these findings identify a previously unappreciated component contributing to long-term antiglycan immunity and support the use of bacteriophage-derived nanoparticles as platforms for vaccines against emerging antibiotic-resistant microorganisms.